Tuesday, November 10, 2009

In the April issue of Nature Biotechnology (subscription only), I reported on a new medicine approved for the treatment of gout -- Uloric (febuxostat) -- the first in 40 years. Three more new drugs are moving through clinical trials and drug-makers are hopeful about their approval by the FDA. The new drugs offer more choices to the limited options doctors have had for decades. And gout, yet another disease of our overconsumptive sedentary lifestyle, is on the rise.

(Image by 19th century caricaturist James Gillray.)

No comments: